SESSION 4: THERAPY Cancer Therapy 2003: Current State of the Century: PAUL A. BUNN, JR., University of Colorado Cancer Center, Denver, Colorado 80262

Sign In to gain access to subscriptions and/or personal tools.

This Article

	Free Full Text (Free PDF) Free
	Alert me when this article is cited
	Alert me if a correction is posted
	Citation Map

Services

	Email this article to a friend
	Similar articles in this journal
	Alert me to new issues of the journal
	Add to Saved Citations
	Download to citation manager
	Request Permissions
	Request Reprints
	Add to My Marked Citations

Citing Articles

	Citing Articles via Google Scholar
	Citing Articles via Scopus

Google Scholar

	Search for Related Content

Social Bookmarking

	What's this?

SESSION 4: THERAPY Cancer Therapy 2003: Current State of the Century

References

Demetri, G.D., M. von Mehren, C.D. Blanke, et al. (2002). "Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors." N Engl J Med 347(7): 472—80.[Abstract/Free Full Text]

Donehower, R.C. (1996). "The Clinical Development of Paclitaxel: A Successful Collaboration of Academia, Industry and the National Cancer Institute." Stem Cells 14(1): 25—8.[Web of Science][Medline] [Order article via Infotrieve]

Grunwald, V. and M. Hidalgo (2003). "Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment." J Natl Cancer Inst 95(12): 851—67.[Abstract/Free Full Text]

Hurwitz, H., L. Fehrenbacher, T. Cartwright, et al. (xxxx) Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Oral presentation, Proc ASCO, 39th Annual Meeting, Chicago, IL, Vol. 22 (abstract #3646).

Jemal, A., T. Murray, A. Samuels, et al. (2003). Cancer statistics. CA Cancer J Clin 53(1): 5—26.[Abstract/Free Full Text]

Mackie, T.R., J. Kapatoes, K. Ruchala, et al. (2003). "Image Guidance for Precise Conformal Radiotherapy." Int J Radiat Oncol Biol Phys 56(1): 89—105.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Manley, P.W., G. Martiny-Baron, J.M. Schlaeppi, and J.M. Wood (2002). "Therapies Directed at Vascular Endothelial Growth Factor." Expert Opin Investig Drug 11(12): 1715—36.

McMasters, K.M., D.S. Reintgen, M.I. Ross, et al. (2001). "Sentinel Lymph Node Biopsy for Melanoma: Controversy Despite Widespread Agreement." J Clin Oncol 19(11): 2851—5.[Abstract/Free Full Text]

O'Brien, S.G., F. Guilhot, R.A. Larson, et al. (2003). "Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia." N Engl J Med 348(11): 994—1004.[Abstract/Free Full Text]

Purdy, J.A. (2000). "Future Directions in 3-D Treatment Planning and Delivery: A Physicist's Perspective." Int J Radiat Oncol Biol Phys 46(1): 3—6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

Schrag, D., K.S. Panageas, E. Riedel, et al. (2003). "Surgeon Volume Compared to Hospital Volume as a Predictor of Outcome Following Primary Colon Cancer Resection." J Surg Oncol 83(2): 68—78.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

" Stat Bite: Effect of Hospital Volume on Operative Mortality for Major Cancer Surgery." (2003). J Natl Cancer Inst 95(10): 701.[Free Full Text]

Vogel, C.L., M.A. Cobleigh, D. Tripathy, et al. (2002). "Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer." J Clin Oncol 20(3): 719—26.[Abstract/Free Full Text]